For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not ...

Corticosteroid therapy must be tapered because of its interactions with the hypothalamic-pituitary-adrenocortical (HPA) axis. The hypothalamus secretes corticotropin releasing factor, which acts ...

In patients with multiple myeloma, combined vincristine, doxorubicin and dexamethasone (VAD) is the most frequently used induction therapy before autologous stem-cell transplantation (ASCT ...

Three cancer agents -- tarlatamab (Imdelltra ... added to pomalidomide (Pomalyst) and dexamethasone for relapsed/refractory multiple myeloma -- met co-primary endpoints of non-inferior response ...

Given the evolving role of trastuzumab deruxtecan (Enhertu) in the treatment of breast cancer, especially those who are HER2 ...

Aspire Pharma (bortezomib, dexamethasone) (confidentiality agreement not signed, not participating) Aurobindo Pharma (bortezomib) (confidentiality agreement not signed, not participating) Bausch & ...

receiving dexamethasone induction, dose reductions do not negatively impact survival, according to a study published online Jan. 2 in Blood. Rahul Banerjee, M.D., from the Fred Hutchinson Cancer ...

The primary corticosteroid used to control cerebral edema is dexamethasone. More than 40 years ago, dexamethasone was used in patients with brain tumors, and it is still used today. Other steroids ...